Kura Oncology Q4 2025 net loss $81M; KOMZIFTI launch revenue $2.1M in first 5 weeks

Kura Oncology, Inc.

Net loss of $81.0M in Q4 2025 vs $19.2M a year ago; full-year net loss $219.4M.
Net product revenue $2.1M from KOMZIFTI in first five weeks of commercial sales post Nov 13 FDA approval.
Collaboration revenue $15.2M (Kyowa Kirin milestones); R&D $64.4M, SG&A $39.1M.
Cash and investments $667.2M; plus $180M in anticipated Kyowa Kirin payments expected to fund through KOMET-017 Phase 3 topline (2028).
2026 milestones include updated KOMET-007 data, KOMET-015 enrollment in GIST, and darlifarnib data in KRAS G12C tumors.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Kura Oncology, Inc. reported the fourth quarter ended December 31, 2025 results: revenue Net product revenue: $2.1 million; Collaboration revenue: $15.2 million.

Period: the fourth quarter ended December 31, 2025
Revenue: Net product revenue: $2.1 million; Collaboration revenue: $15.2 million
Result: reported results

Exact text from the filing

Fourth Quarter 2025 Financial Results • Net product revenue: $2.1 million (first five weeks of commercial sales following November 13 approval of KOMZIFTI). • Collaboration revenue: $15.2 million, compared to $53.9 million for Q4

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Kura Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-092465

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.